Glonghui December 8 | Walterdyne (000915.SZ) announced that recently, Shandong Dyne Marine Biopharmaceuticals Co., Ltd. (Dyne Pharmaceutical for short), a subsidiary of Shandong Walterdyne Health Co., Ltd., received the “Drug Registration Certificate” (certificate number: 2023S01930) for atomoxetine hydrochloride capsules issued by the State Drug Administration. This product is used to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
华特达因(000915.SZ)：达因药业获得盐酸托莫西汀胶囊的药品注册证书
Walterdyne (000915.SZ): Dyne Pharmaceutical obtains drug registration certificate for atomoxetine hydrochloride capsules
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.